Share this video  

ESMO 2020 | SECOMBIT: sequencing of targeted agents/immunomodulatory Abs in metastatic BRAFV600-mutated melanoma

Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, discusses the first report of efficacy and safety from the Phase II SECOMBIT trial (Sequential COMBo Immuno and Targeting therapy study) (NCT02631447), which evaluates the best sequencing approach with the combination of target agents (encorafenib plus binimetinib) and the combination of immunomodulatory antibodies (ipilimumab plus nivolumab) in patients with metastatic melanoma and BRAF V600 mutation. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).